ClinicalTrials.gg
CompletedNCT00347360Updated Dec 26, 2016Results posted

The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial

A Phase 3 interventional study of lisinopril and carvedilol controlled release formulation in Hypertension, sponsored by GlaxoSmithKline. Completed at 151 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-26.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
654
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing lisinopril in Hypertension — none open to participants now, none under way, none of them phase 3. Lisinopril · Hypertension.

Enrollment
3rd of 30
654 · median 55
Started
2006
with 1 other
Phase 3
4 of 30
none open now
Registered
7th of 30
by date
Lead sponsor
5 of 30
GlaxoSmithKline

Among the 30 studies testing lisinopril in Hypertension, this one is the 3rd largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 3, and was the 7th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 30 studies testing lisinopril in Hypertension is open now. The open studies under Hypertension, anywhere →

About lisinopril

Lisinopril: first FDA approval 1987 (PRINIVIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing lisinopril in Hypertension as a file.
02

Study summary

This is a randomized, double-blind, double-dummy, parallel group trial employing 15 cells of a 4x4 factorial design (no placebo)to compare the hypertensive effects in patients with Stage 1 and Stage 2 hypertension of carvedilol (20, 40 or 80 mg daily) alone, lisinopril (10, 20 or 40 mg daily) alone, and all combinations of the doses.

Read the detailed description

A Randomized, Double-Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess the Efficacy and Safety of up to Six Weeks Treatment with 20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG CR) or 10mg, 20mg, or 40mg QD Doses of Lisinopril (ZESTRIL) or a Combination of One of the Doses of Each Medication

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • carvedilol
  • hypertension
  • lisinopril
  • factorial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has given signed .
  • Subject is male or female 18 years of age at the time informed consent is signed.
  • At the Screening visit, subject has a documented history or current presentation with stage 1 or stage 2 hypertension (see Section 15.1, Appendix 1 and Section 15.4, Appendix 4) which meets one of the following criteria. Note: All blood pressures are mean sitting cuff pressures:

Documented history of hypertension and receiving two antihypertensive medications with mean sDBP \<90 mmHg or for diabetic subjects (defined as having an established diagnosis of diabetes or receiving treatment for diabetes), mean sDBP \<80 mmHg. Subjects taking beta blockers, clonidine, or other antihypertensive medications where abrupt discontinuation would be of clinical concern must be tapered off the medication during the /Placebo Run-in phase to avoid rebound hypertension. All subjects must be able to be safely withdrawn from all antihypertensive treatment during the Washout/Placebo Run-in phase. Subjects should not be enrolled if the investigator thinks it is likely the subject's mean sDBP will exceed 109 mmHg or their mean sSBP will exceed 180 mmHg during the Washout/Placebo Run-in phase (NOTE: A combination drug containing two antihypertensive agents represents two antihypertensive medications [e.g., Hyzaar is losartan potassium AND hydrochlorothiazide, therefore, counts as two antihypertensive medications].) OR Receiving one antihypertensive medication with mean sDBP =109 mmHg and can be safely withdrawn from all antihypertensive medication during the Washout/Placebo Run-in phase. Any subject who is receiving beta-blockers, clonidine, or other antihypertensive medications where abrupt discontinuation would be of clinical concern must have the dose tapered down during the Washout/Placebo Run-in phase to avoid rebound hypertension. All subjects must be able to be safely withdrawn from all antihypertensive treatment during the Washout/Placebo Run-in phase. Subjects should not be enrolled if the investigator thinks it is likely the subject's mean sDBP will exceed 109 mmHg or their mean sSBP will exceed 180 mmHg during the Washout/Placebo Run-in phase.

(NOTE: A combination drug containing two antihypertensive agents represents two antihypertensive medications [e.g., Hyzaar is losartan potassium AND hydrochlorothiazide, therefore, counts as two antihypertensive medications].

OR Untreated/newly diagnosed subjects: mean sDBP =95 and =109, or for diabetic subjects, mean sDBP =85 and =109 (see Section 15.1, Appendix 1). If newly diagnosed, must have qualifying blood pressure confirmed on two consecutive visits with the mean sDBP value not differing more than 8 mmHg. (Previously untreated subjects include subjects who have not been treated for hypertension in the last two months.).

  • At Baseline:

DAY BEFORE RANDOMIZATION: Prior to having the baseline ABPM equipment placed, subject has mean sitting cuff DBP that is ≥93 and ≤111 mmHg (or for diabetic subjects, ≥83 and ≤111 mmHg). Subjects who were taking antihypertensive medication at Screening and do not meet this criterion after one week (or 5 half-lives, whichever is longer), can return in one week ±1day and have his/her blood pressure evaluated again for this inclusion criterion.

AND

RANDOMIZATON DAY: After completion of the ABPM assessment, subject meets the following ABPM (both 12 hr and 24 hr) criteria (see Section 15.1, Appendix 1):

  • Mean 12-hour daytime (9 AM to 9 PM) DBP ≥90 and ≤109mmHg (or for diabetic subjects, ≥80 and ≤109mmHg)
  • At least 75% of the programmed readings properly recorded over 24-hour monitoring period
  • No more than two non-consecutive hours with less than two successful readings per hour while awake, and no more than two consecutive hours with less than one successful reading per hour during the sleep period over the 24-hour monitoring period
  • At least two successful readings per hour for three of the last four hours of recording (trough period i.e., 20-24 hour during which subjects must be awake) with a total of at least 7 successful readings over this period.

Exclusion criteria

Exclusion Criteria:

  • Subject is taking ≥3 antihypertensive medications. (NOTE: A combination drug containing two antihypertensive agents represents two antihypertensive medications [e.g., Hyzaar is losartan potassium AND hydrochlorothiazide, therefore, counts as two antihypertensive medications].)
  • Subject has DBP =90 mmHg (or for diabetic subjects, DBP =80 mmHg) on two antihypertensive medications.
  • Subject has any known to ACE inhibitors (e.g., ACE-induced cough, angioedema or negative renal effects), or blocker treatment.
  • Hyperkalemia or history of hyperkalemia resulting from either Type IV RTA (renal tubular acidosis) or previous ACEi therapy.
  • Is female of . NOTE: Female subjects who are (i.e., no menstrual period for a minimum of 12 months prior to Screening) or surgically sterilized are eligible for the study. If judged appropriate, a postmenopausal woman may be required to have a documented negative urine pregnancy test.
  • Subject has malignant (accelerated) hypertension, history of malignant hypertension, or secondary forms of hypertension.
  • Subject has mean sitting SBP =180 mmHg.
  • Subject has advanced hypertensive retinopathy (Keith Wagner Grade IV).
  • Subject has Type 1 diabetes mellitus, or those with Type 2 having ≥9% at Screening.
  • Subject has uncorrected primary obstructive or severe regurgitative valvular disease, nondilated (restrictive) or hypertrophic cardiomyopathies.
  • Subject has any of the following conditions:

uncontrollable or symptomatic arrhythmias unstable angina or angina treated with a beta-blocker sick sinus syndrome or second or third degree heart block (unless treated with a permanent, functioning pacemaker) bradycardia (sitting heart rate \<55 bpm) history of myocardial infarction stroke within 3 months of Screening

  • Subject is in atrial fibrillation.
  • Subject has Congestive Heart Failure (New York Heart Association) class II-IV [The Criteria Committee of the New York Heart Association, 1994].
  • Current clinical evidence of asthma or (e.g., severe emphysema or chronic bronchitis) requiring long term use of inhaled oral bronchodilator or drug therapy; also subjects with a history of bronchospastic disease not undergoing active therapy in whom, in the investigator's opinion, treatment with the study medication could provoke bronchospasm; or requirement for or anticipated treatment with beta-2 agonist therapy (e.g., albuterol [Ventolin, Proventil], metaproterenol [Alupent], pirbuterol [Maxair], terbutaline [Brethaire], isoetharine [Bronkosol], and Levalbuterol [Xopenex]).
  • Subject has evidence of any of the following diseases that could impair the absorption, metabolism, or excretion of orally-administered medication:

renal disease defined as estimated (eGFR) \<30mL/min per 1.73 m2 hepatic disease (i.e., or AST levels greater than three times the , history of hepatic impairment, or by clinical assessment) chronic biliary disorders gastric bypass surgery

  • Subject has endocrine disorders that affect blood pressure (e.g., pheochromocytoma, active and untreated hypo- or hyperthyroidism).
  • Subject has systemic disease, including cancer, with reduced (\<12 months) .
  • Subject has used an drug within 30 days or 5 half-lives (whichever is longer) preceding Screening.
  • Subject has a history of a psychological illness/condition that would interfere with their ability to understand or complete the requirements of the study.
  • Subject has any condition that, in the opinion of the Investigator and/or the GSK Medical Monitor, places the subject at an unacceptable risk as a participant in this trial.
  • Subject is receiving ongoing treatment or is anticipated to receive treatment with any of the following medications during treatment with double blind study medication:

any antihypertensive medication except for assigned study medication. This would include alpha blockers or other medications that may be used to treat hypertension and other conditions unrelated to hypertension; monoamine oxidase (MAO) inhibitors; any Class I or III antiarrhythmic; beta-2-agonists.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
654 participants (actual)

Study arms

  • Experimental
    lisinopril

    lisinopril

    Drug: lisinopril

  • Experimental
    carvedilol

    carvedilol controlled release formulation

    Drug: carvedilol controlled release formulation

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure

    Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean diastolic blood pressure (DBP).

    Time frame: Baseline, Week 6.

  2. Change From Baseline to Week 6 in Trough Diastolic Blood Pressure

    Trough ABPM was the average across 20-24 hr after dosing for each subject.

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Change From Baseline to Week 6 in 24 Hour Mean Systolic Blood Pressure

    Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean systolic blood pressure (SBP).

    Time frame: Baseline, Week 6

  2. Change From Baseline to Week 6 in Trough Systolic Blood Pressure

    Trough ABPM was the average across 20-24 hr after dosing for each subject.

    Time frame: Baseline, Week 6

  3. Dose-response Treatment Estimates: Change From Baseline to Week 6 in 24 Hour Mean DBP by ABPM (Ambulatory Blood Pressure Monitoring)

    Evaluation of the dose-response relationship between incremental doses of carvedilol CR and lisinopril and mean 24-hr ABPM DBP.

    Time frame: Baseline, Week 6

  4. Change From Baseline to Week 6 in Trough to Peak Ratios of DBP by 24 Hour ABPM (Ambulatory Blood Pressure Monitoring)

    Trough (20-24 hr) to peak (3-7 hr) ratios of DBP were examined in order to evaluate the extent to which once-daily criteria were met (ie trough:peak \> 50%). Trough to peak ratios were calculated from change trough mean/change peak mean x 100.

    Time frame: Baseline, Week 6

  5. Overall Description of Safety in Each Treatment Group Using Adverse Events, Laboratory Evaluations, ECG Changes, Vital Sign Changes, and Withdrawal Rates.

    Refer to Adverse Event section for safety information.

    Time frame: Weeks 1 through 48

  6. Change From Baseline to Week 6 in Mean SBP and DBP Measured in Morning by 24 Hour ABPM

    Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the morning. The morning assessment period started at or after 6 am and ended immediately before 12 noon.

    Time frame: Morning BP, Baseline, Week 6

  7. Change From Baseline to Week 6 in Mean SBP and DBP Measured in Afternoon by 24hr ABPM

    Mean changes from Baseline to Week 6 in SBP and DBP measured by 24hr ABPM at the end of up-titration recorded in the afternoon. The afternoon assessment period started at or after 12 noon and ended immediately before 6 pm.

    Time frame: Afternoon BP, Baseline, Week 6

  8. Change From Baseline to Week 6 in Mean SBP and DBP Measured at Night by 24hr ABPM

    Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the night. The night-time assessment period started at the time of the first reading at or after 6 pm and ended immediately before 6 am on the following day.

    Time frame: Night BP, Baseline, Week 6

  9. Change From Baseline to Week 6 in Mean Trough Sitting SBP and Sitting DBP by Cuff Assessment

    Analysis of Change from Baseline to Week 6 in Mean sSBP and sDBP by Cuff Assessments at Drug Trough (20-24 hr) at End of Treatment Titration

    Time frame: Baseline, Week 6

  10. Diastolic Responders, Defined as ≥ 10 mmHg Sitting (s)DBP Reduction From Baseline or a sDBP of <90 / 80 Millimeters (mm) of Mercury (Hg) for Non Diabetic / Diabetic Subjects Respectively (Based on Cuff Trough Measures)

    Time frame: Week 6

07

Results

Posted Nov 9, 2009

Participant flow

Participant flow — Overall Study
MilestoneLisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40
Started444343434444444344444443444443
Completed393537303936374038353937343639
Not completed58613587369561084
Withdrew: Adverse event120412202331322
Withdrew: Lost to follow-up000211011200100
Withdrew: Protocol violation231212001200010
Withdrew: Withdrawal by subject012412111103421
Withdrew: Lack of efficacy113101011000000
Withdrew: Reason not listed/blank100000100000010
Withdrew: Per sponsors instruction010000000000000
Withdrew: P.i. recommended due to blood pressure000010000000000
Withdrew: Subject did not meet end of study abpm000000100010110
Withdrew: Abnormal lab values000000100000000
Withdrew: Pi recommended early withdrawal000000000100000
Withdrew: Did not meet criteria before abpm000000000010000
Withdrew: Randomized in error000000000001000
Withdrew: Failed inclusion criteria #4000000000001000
Withdrew: Prolonged duration between visits000000000000100
Withdrew: Subject left town, ran out of study drug000000000000010
Withdrew: Subject refuse to sign updated consent000000000000001
Withdrew: Visits conflicted with new job000000100000000

Outcome measures

PrimaryChange From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure

Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean diastolic blood pressure (DBP).

Time frame:
Baseline, Week 6.
Reported as:
Mean · mmHg
Change From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure
mmHgLisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40
Change From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure-5.79 ± 5.922-8.11 ± 8.811-7.37 ± 5.914-4.40 ± 5.182-7.61 ± 4.880-6.52 ± 6.408-9.29 ± 7.226-8.57 ± 6.585-10.19 ± 6.899-9.36 ± 7.426-10.96 ± 8.388-10.37 ± 7.234-10.93 ± 5.517-11.09 ± 8.719-11.92 ± 6.887
Statistical analysis
  • Lisinopril 10 vs Lisinopril 20 vs Lisinopril 40 vs Carvedilol Controlled Release 20 vs Carvedilol Controlled Release 40 vs Carvedilol Controlled Release 80 vs Carvedilol Controlled Release 20 Lisinopril 10 vs Carvedilol Controlled Release 20 Lisinopril 20 vs Carvedilol Controlled Release 20 Lisinopril 40 vs Carvedilol Controlled Release 40 Lisinopril 10 vs Carvedilol Controlled Release 40 Lisinopril 20 vs Carvedilol Controlled Release 40 Lisinopril 40 vs Carvedilol Controlled Release 80 Lisinopril 10 vs Carvedilol Controlled Release 80 Lisinopril 20 vs Carvedilol Controlled Release 80 Lisinopril 40 · Hung AVE test, see comments · p = >0.1Hung AVE Test Statistic: -0.41499. Tests an average of the minimum gains (in response) for the 9 combination cells over corresponding monotherapies.
PrimaryChange From Baseline to Week 6 in Trough Diastolic Blood Pressure

Trough ABPM was the average across 20-24 hr after dosing for each subject.

Time frame:
Baseline, Week 6
Reported as:
Mean · mmHg
Change From Baseline to Week 6 in Trough Diastolic Blood Pressure
mmHgLisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40
Change From Baseline to Week 6 in Trough Diastolic Blood Pressure-6.40 ± 7.982-6.08 ± 8.735-8.16 ± 7.299-2.34 ± 7.060-7.76 ± 8.285-5.26 ± 9.530-5.14 ± 7.002-6.36 ± 9.080-7.22 ± 11.284-6.79 ± 9.210-7.76 ± 11.202-4.90 ± 8.508-6.54 ± 8.305-7.26 ± 9.345-8.42 ± 7.903
Statistical analysis
  • Lisinopril 10 vs Lisinopril 20 vs Lisinopril 40 vs Carvedilol Controlled Release 20 vs Carvedilol Controlled Release 40 vs Carvedilol Controlled Release 80 vs Carvedilol Controlled Release 20 Lisinopril 10 vs Carvedilol Controlled Release 20 Lisinopril 20 vs Carvedilol Controlled Release 20 Lisinopril 40 vs Carvedilol Controlled Release 40 Lisinopril 10 vs Carvedilol Controlled Release 40 Lisinopril 20 vs Carvedilol Controlled Release 40 Lisinopril 40 vs Carvedilol Controlled Release 80 Lisinopril 10 vs Carvedilol Controlled Release 80 Lisinopril 20 vs Carvedilol Controlled Release 80 Lisinopril 40 · Hung AVE test, see comments · p = >0.1Hung AVE Test Statistic: -0.00485. Tests an average of the minimum gains (in response) for the 9 combination cells over corresponding monotherapies.
SecondaryChange From Baseline to Week 6 in 24 Hour Mean Systolic Blood Pressure

Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean systolic blood pressure (SBP).

Time frame:
Baseline, Week 6
Reported as:
Mean · mmHg
Change From Baseline to Week 6 in 24 Hour Mean Systolic Blood Pressure
mmHgLisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40
Change From Baseline to Week 6 in 24 Hour Mean Systolic Blood Pressure-9.19 ± 9.415-13.58 ± 16.429-10.60 ± 8.842-6.15 ± 6.887-9.84 ± 8.471-10.38 ± 8.204-12.06 ± 11.058-11.58 ± 11.112-14.16 ± 10.783-11.68 ± 10.218-14.03 ± 11.954-13.90 ± 10.237-15.60 ± 9.777-15.93 ± 12.501-15.59 ± 11.055
SecondaryChange From Baseline to Week 6 in Trough Systolic Blood Pressure

Trough ABPM was the average across 20-24 hr after dosing for each subject.

Time frame:
Baseline, Week 6
Reported as:
Mean · mmHg
Change From Baseline to Week 6 in Trough Systolic Blood Pressure
mmHgLisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40
Change From Baseline to Week 6 in Trough Systolic Blood Pressure-9.47 ± 13.301-7.52 ± 12.221-9.54 ± 9.968-0.96 ± 11.447-9.27 ± 12.362-5.68 ± 14.539-6.44 ± 9.739-9.27 ± 13.582-9.88 ± 14.356-8.87 ± 11.954-8.11 ± 13.732-5.82 ± 13.878-9.80 ± 11.196-10.74 ± 12.813-10.00 ± 12.091
SecondaryDose-response Treatment Estimates: Change From Baseline to Week 6 in 24 Hour Mean DBP by ABPM (Ambulatory Blood Pressure Monitoring)

Evaluation of the dose-response relationship between incremental doses of carvedilol CR and lisinopril and mean 24-hr ABPM DBP.

Time frame:
Baseline, Week 6
Reported as:
Mean · mmHg
Dose-response Treatment Estimates: Change From Baseline to Week 6 in 24 Hour Mean DBP by ABPM (Ambulatory Blood Pressure Monitoring)
mmHgLisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40
Dose-response Treatment Estimates: Change From Baseline to Week 6 in 24 Hour Mean DBP by ABPM (Ambulatory Blood Pressure Monitoring)-5.77 ± 0.821-7.55 ± 0.717-7.49 ± 0.877-5.11 ± 0.821-6.61 ± 0.718-7.13 ± 0.925-8.08 ± 0.472-9.83 ± 0.536-9.71 ± 0.657-9.55 ± 0.534-11.3 ± 0.645-11.1 ± 0.702-10.0 ± 0.696-11.7 ± 0.722-11.4 ± 1.042
SecondaryChange From Baseline to Week 6 in Trough to Peak Ratios of DBP by 24 Hour ABPM (Ambulatory Blood Pressure Monitoring)

Trough (20-24 hr) to peak (3-7 hr) ratios of DBP were examined in order to evaluate the extent to which once-daily criteria were met (ie trough:peak \> 50%). Trough to peak ratios were calculated from change trough mean/change peak mean x 100.

Time frame:
Baseline, Week 6
Reported as:
Number · trough:peak ratio x 100%
Change From Baseline to Week 6 in Trough to Peak Ratios of DBP by 24 Hour ABPM (Ambulatory Blood Pressure Monitoring)
trough:peak ratio x 100%Lisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40
Change From Baseline to Week 6 in Trough to Peak Ratios of DBP by 24 Hour ABPM (Ambulatory Blood Pressure Monitoring)133.3361.04114.4534.1171.0049.6744.5049.4659.4754.7152.8637.9341.9553.5452.07
SecondaryOverall Description of Safety in Each Treatment Group Using Adverse Events, Laboratory Evaluations, ECG Changes, Vital Sign Changes, and Withdrawal Rates.

Refer to Adverse Event section for safety information.

Time frame:
Weeks 1 through 48

Results for this outcome have not been posted.

SecondaryChange From Baseline to Week 6 in Mean SBP and DBP Measured in Morning by 24 Hour ABPM

Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the morning. The morning assessment period started at or after 6 am and ended immediately before 12 noon.

Time frame:
Morning BP, Baseline, Week 6
Reported as:
Mean · mmHg
Change From Baseline to Week 6 in Mean SBP and DBP Measured in Morning by 24 Hour ABPM
mmHgLisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40
Change in Morning SBP from Baseline to Week 6-9.37 ± 9.564-14.53 ± 17.166-10.76 ± 9.112-6.23 ± 9.159-10.42 ± 8.815-13.70 ± 10.056-13.89 ± 12.288-10.22 ± 12.734-14.50 ± 12.031-12.78 ± 14.700-14.29 ± 14.136-14.84 ± 13.383-17.09 ± 13.194-14.52 ± 15.111-17.12 ± 14.016
Change in Morning DBP from Baseline to Week 6-6.12 ± 8.457-9.20 ± 10.516-7.62 ± 8.033-5.01 ± 7.141-6.82 ± 6.279-7.53 ± 8.206-9.21 ± 9.474-7.86 ± 8.416-10.04 ± 8.489-8.79 ± 10.902-11.15 ± 10.411-9.96 ± 10.730-11.95 ± 8.060-10.71 ± 11.012-12.46 ± 8.763
SecondaryChange From Baseline to Week 6 in Mean SBP and DBP Measured in Afternoon by 24hr ABPM

Mean changes from Baseline to Week 6 in SBP and DBP measured by 24hr ABPM at the end of up-titration recorded in the afternoon. The afternoon assessment period started at or after 12 noon and ended immediately before 6 pm.

Time frame:
Afternoon BP, Baseline, Week 6
Reported as:
Mean · mmHg
Change From Baseline to Week 6 in Mean SBP and DBP Measured in Afternoon by 24hr ABPM
mmHgLisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40
Change in Afternoon SBP from Baseline to Week 6-9.68 ± 11.399-17.21 ± 19.772-10.53 ± 13.359-9.69 ± 10.094-13.34 ± 9.669-13.76 ± 11.796-13.96 ± 13.128-15.54 ± 13.503-16.38 ± 13.285-14.51 ± 13.433-17.97 ± 14.622-17.82 ± 13.042-20.91 ± 13.704-20.46 ± 17.611-19.36 ± 14.893
Change in Afternoon DBP from Baseline to Week 6-5.62 ± 7.969-10.25 ± 12.250-6.67 ± 7.800-6.27 ± 8.910-10.12 ± 6.555-8.38 ± 7.787-11.28 ± 8.998-12.04 ± 8.132-11.59 ± 10.112-12.18 ± 9.905-14.03 ± 9.425-12.54 ± 8.893-15.12 ± 8.437-13.87 ± 12.997-15.02 ± 9.197
SecondaryChange From Baseline to Week 6 in Mean SBP and DBP Measured at Night by 24hr ABPM

Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the night. The night-time assessment period started at the time of the first reading at or after 6 pm and ended immediately before 6 am on the following day.

Time frame:
Night BP, Baseline, Week 6
Reported as:
Mean · mmHg
Change From Baseline to Week 6 in Mean SBP and DBP Measured at Night by 24hr ABPM
mmHgLisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40
Change in Night SBP from Baseline to Week 6-9.01 ± 10.635-11.58 ± 16.103-10.38 ± 8.600-4.28 ± 8.018-7.70 ± 10.178-7.71 ± 9.627-10.37 ± 11.517-9.94 ± 11.220-12.64 ± 11.301-10.02 ± 10.256-11.87 ± 12.031-11.25 ± 11.462-12.08 ± 9.486-14.12 ± 12.151-13.06 ± 10.651
Change in Night DBP from Baseline to Week 6-5.83 ± 6.602-6.78 ± 8.251-7.49 ± 6.085-3.20 ± 5.340-6.49 ± 5.723-5.34 ± 7.187-8.11 ± 7.260-7.03 ± 6.853-9.36 ± 7.068-8.23 ± 7.458-9.34 ± 8.960-9.09 ± 7.321-8.27 ± 6.002-9.88 ± 8.161-10.14 ± 7.468
SecondaryChange From Baseline to Week 6 in Mean Trough Sitting SBP and Sitting DBP by Cuff Assessment

Analysis of Change from Baseline to Week 6 in Mean sSBP and sDBP by Cuff Assessments at Drug Trough (20-24 hr) at End of Treatment Titration

Time frame:
Baseline, Week 6
Reported as:
Mean · mmHg
Change From Baseline to Week 6 in Mean Trough Sitting SBP and Sitting DBP by Cuff Assessment
mmHgLisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40
Change in sSBP by Cuff from Baseline to Week 6-11.97 ± 13.671-10.85 ± 12.975-13.09 ± 10.200-5.68 ± 10.074-5.07 ± 15.610-8.88 ± 15.179-9.54 ± 14.373-11.84 ± 16.943-13.43 ± 15.279-9.79 ± 14.481-11.26 ± 15.056-13.49 ± 17.626-6.42 ± 16.409-9.00 ± 14.541-14.58 ± 16.176
Change in sDBP by Cuff from Baseline to Week 6-7.45 ± 13.671-5.32 ± 8.969-10.35 ± 7.627-6.87 ± 5.671-5.70 ± 9.760-7.54 ± 8.469-5.66 ± 8.949-10.02 ± 10.384-10.28 ± 8.543-8.73 ± 10.771-10.89 ± 10.757-9.63 ± 11.073-8.22 ± 9.203-9.45 ± 11.204-10.95 ± 8.624
SecondaryDiastolic Responders, Defined as ≥ 10 mmHg Sitting (s)DBP Reduction From Baseline or a sDBP of <90 / 80 Millimeters (mm) of Mercury (Hg) for Non Diabetic / Diabetic Subjects Respectively (Based on Cuff Trough Measures)
Time frame:
Week 6
Reported as:
Number · participants
Diastolic Responders, Defined as ≥ 10 mmHg Sitting (s)DBP Reduction From Baseline or a sDBP of <90 / 80 Millimeters (mm) of Mercury (Hg) for Non Diabetic / Diabetic Subjects Respectively (Based on Cuff Trough Measures)
participantsLisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40
Diastolic Responders, Defined as ≥ 10 mmHg Sitting (s)DBP Reduction From Baseline or a sDBP of <90 / 80 Millimeters (mm) of Mercury (Hg) for Non Diabetic / Diabetic Subjects Respectively (Based on Cuff Trough Measures)222327201817202825302227282428

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lisinopril 10———
Lisinopril 20———
Lisinopril 40———
Carvedilol Controlled Release 20———
Carvedilol Controlled Release 40———
Carvedilol Controlled Release 80———
Carvedilol Controlled Release 20 Lisinopril 10———
Carvedilol Controlled Release 20 Lisinopril 20———
Carvedilol Controlled Release 20 Lisinopril 40———
Carvedilol Controlled Release 40 Lisinopril 10———
Carvedilol Controlled Release 40 Lisinopril 20———
Carvedilol Controlled Release 40 Lisinopril 40———
Carvedilol Controlled Release 80 Lisinopril 10———
Carvedilol Controlled Release 80 Lisinopril 20———
Carvedilol Controlled Release 80 Lisinopril 40———
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventLisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40
HyperhidrosisSkin and subcutaneous tissue disorders0/441/420/430/430/430/440/440/430/440/440/440/420/440/440/42
Hypertension (worsening)Vascular disorders0/440/420/430/430/430/440/440/430/440/440/440/420/440/441/42
LethargyNervous system disorders0/441/420/430/430/430/440/440/430/440/440/440/420/440/440/42
ListlessPsychiatric disorders0/441/420/430/430/430/440/440/430/440/440/440/420/440/440/42
NauseaGastrointestinal disorders0/441/420/430/430/430/440/440/430/440/440/440/420/440/440/42
AlcoholismPsychiatric disorders0/440/420/431/430/430/440/440/430/440/440/440/420/440/440/42
DepressionPsychiatric disorders0/440/420/431/430/430/440/440/430/440/440/440/420/440/440/42
Drug abusePsychiatric disorders0/440/420/431/430/430/440/440/430/440/440/440/420/440/440/42
HeadacheNervous system disorders0/440/420/431/430/430/440/440/430/440/440/440/420/440/440/42
Ischaemic cerebral infarctionNervous system disorders0/440/420/430/430/430/440/441/430/440/440/440/420/440/440/42
Most frequent other events
Showing 10 of 15
Most frequent other events
EventLisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40
HeadacheNervous system disorders4/441/427/437/435/434/444/444/435/443/443/441/422/447/442/42
CoughRespiratory, thoracic and mediastinal disorders6/443/421/431/430/430/442/442/434/442/447/445/421/442/442/42
FatigueGeneral disorders1/443/421/431/433/432/441/442/431/443/444/443/422/447/442/42
DizzinessNervous system disorders3/443/423/433/434/433/441/443/436/443/445/443/422/444/440/42
Upper respiratory tract infectionInfections and infestations3/440/422/430/430/430/443/441/435/441/441/441/421/440/441/42
SinusitisInfections and infestations0/440/420/431/431/430/440/440/430/440/440/440/420/445/440/42
DiarrhoeaGastrointestinal disorders1/442/420/431/430/430/441/441/432/443/442/442/421/444/441/42
MyalgiaMusculoskeletal and connective tissue disorders1/440/422/430/430/430/440/440/434/440/440/440/420/440/440/42
NasopharyngitisInfections and infestations0/441/421/431/430/431/441/440/431/441/443/441/420/441/443/42
Sinus congestionRespiratory, thoracic and mediastinal disorders0/440/421/430/431/431/440/440/430/440/441/441/420/440/443/42

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40Total
Mean52.3 ± 10.5353.3 ± 10.6951.1 ± 10.7053.2 ± 9.4154.1 ± 10.9454.3 ± 8.6453.3 ± 9.6055.5 ± 8.3953.5 ± 10.5151.9 ± 9.0851.5 ± 9.3257.9 ± 9.2752.5 ± 11.1150.9 ± 9.5151.5 ± 8.6953.1 ± 9.86
Gender
Gender(Participants)Lisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40Total
Female171715201219131814131318151414232
Male272628233225312530313125293029422
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lisinopril 10Lisinopril 20Lisinopril 40Carvedilol Controlled Release 20Carvedilol Controlled Release 40Carvedilol Controlled Release 80Carvedilol Controlled Release 20 Lisinopril 10Carvedilol Controlled Release 20 Lisinopril 20Carvedilol Controlled Release 20 Lisinopril 40Carvedilol Controlled Release 40 Lisinopril 10Carvedilol Controlled Release 40 Lisinopril 20Carvedilol Controlled Release 40 Lisinopril 40Carvedilol Controlled Release 80 Lisinopril 10Carvedilol Controlled Release 80 Lisinopril 20Carvedilol Controlled Release 80 Lisinopril 40Total
African American/African Heritage10149161113121112181413161411194
American Indian or Alaska Native0000000000010102
Asian31312221223133433
Native Hawaiian or other Pacific Islander1000000000000001
White292831263029303029232727252627417
Race not provided by patient1000100111010017
08

Study locations

151 sites
  • GSK Investigational Site
    Anniston, Alabama 36207, United States
  • GSK Investigational Site
    Birmingham, Alabama 35215, United States
  • GSK Investigational Site
    Birmingham, Alabama 35216, United States
  • GSK Investigational Site
    Birmingham, Alabama 35235, United States
  • GSK Investigational Site
    Birmingham, Alabama 35242, United States
  • GSK Investigational Site
    Haleyville, Alabama 35565, United States
  • GSK Investigational Site
    Mobile, Alabama 36617, United States
  • GSK Investigational Site
    Muscle Shoals, Alabama 35662, United States
  • GSK Investigational Site
    Chandler, Arizona 85225, United States
  • GSK Investigational Site
    Gilbert, Arizona 85296, United States
  • GSK Investigational Site
    Glendale, Arizona 85308, United States
  • GSK Investigational Site
    Mesa, Arizona 85206, United States
  • GSK Investigational Site
    Phoenix, Arizona, Arizona 86106, United States
  • GSK Investigational Site
    Phoenix, Arizona 85023, United States
  • GSK Investigational Site
    Phoenix, Arizona 85032, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85251, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85260, United States
  • GSK Investigational Site
    Sun City, Arizona 85351, United States
  • GSK Investigational Site
    Tucson, Arizona 85712, United States
  • GSK Investigational Site
    Tucson, Arizona 85741, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72204, United States
  • GSK Investigational Site
    Searcy, Arkansas 72143, United States
  • GSK Investigational Site
    Beuna Park, California 90620, United States
  • GSK Investigational Site
    Beverly Hills, California 90211, United States
  • GSK Investigational Site
    Burbank, California 91505, United States
  • GSK Investigational Site
    Carlsbad, California 92008, United States
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Fresno, California 93703, United States
  • GSK Investigational Site
    Loma Linda, California 92354, United States
  • GSK Investigational Site
    Mission Viejo, California 92691, United States
  • GSK Investigational Site
    Pico Rivera, California 90660, United States
  • GSK Investigational Site
    Rancho Cordova, California 95670, United States
  • GSK Investigational Site
    San Diego, California 92117, United States
  • GSK Investigational Site
    San Diego, California 92128, United States
  • GSK Investigational Site
    Santa Ana, California 92705, United States
  • GSK Investigational Site
    Vista, California 92084, United States
  • GSK Investigational Site
    Walnut Creek, California 94598, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80904, United States
  • GSK Investigational Site
    Denver, Colorado 80206, United States
  • GSK Investigational Site
    Wilmington, Delaware 19805, United States
  • GSK Investigational Site
    Washington, District of Columbia 20017, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Hialeah, Florida 33013, United States
  • GSK Investigational Site
    Hollywood, Florida 33023, United States
  • GSK Investigational Site
    Jacksonville Beach, Florida 32250, United States
  • GSK Investigational Site
    Jacksonville, Florida 32205, United States
  • GSK Investigational Site
    Miami, Florida 33156, United States
  • GSK Investigational Site
    Miami, Florida 33169, United States
  • GSK Investigational Site
    Palm Harbor, Florida 34684, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33024, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33027, United States
  • GSK Investigational Site
    Sarasota, Florida 34239, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
  • GSK Investigational Site
    Gainesville, Georgia 30501, United States
  • GSK Investigational Site
    Marietta, Georgia 30066, United States
  • GSK Investigational Site
    Sandersville, Georgia 31082, United States
  • GSK Investigational Site
    Savannah, Georgia 31406, United States
  • GSK Investigational Site
    Aurora, Illinois 60504, United States
  • GSK Investigational Site
    Chicago, Illinois 60607, United States
  • GSK Investigational Site
    Chicago, Illinois 60610, United States
  • GSK Investigational Site
    Melrose Park, Illinois 60160, United States
  • GSK Investigational Site
    Avon, Indiana 46123, United States
  • GSK Investigational Site
    Bloomington, Indiana 47102, United States
  • GSK Investigational Site
    Fort Wayne, Indiana 46804, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46250, United States
  • GSK Investigational Site
    Ames, Iowa 50010, United States
  • GSK Investigational Site
    Wichita, Kansas 67205, United States
  • GSK Investigational Site
    Slidell, Louisiana 70458, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01103, United States
  • GSK Investigational Site
    Taunton, Massachusetts 02780., United States
  • GSK Investigational Site
    Bingham Farms, Michigan 48025, United States
  • GSK Investigational Site
    Brooklyn Center, Minnesota 55430, United States
  • GSK Investigational Site
    Missoula, Montana 59808, United States
  • GSK Investigational Site
    O Fallon, Montana 63366, United States
  • GSK Investigational Site
    Omaha, Nebraska 68131, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89016, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89119, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89128, United States
  • GSK Investigational Site
    Cherry Hill, New Jersey 08034, United States
  • GSK Investigational Site
    Edison, New Jersey 08817, United States
  • GSK Investigational Site
    Ridgewood, New Jersey 7450, United States
  • GSK Investigational Site
    Voorhees, New Jersey 08043, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87102, United States
  • GSK Investigational Site
    Brooklyn, New York 11203, United States
  • GSK Investigational Site
    Buffalo, New York 14215, United States
  • GSK Investigational Site
    Kingston, New York 12401, United States
  • GSK Investigational Site
    Lewinston, New York 14092, United States
  • GSK Investigational Site
    Tonawanda, New York 14150-1810, United States
  • GSK Investigational Site
    Asheville, North Carolina 28801, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28211, United States
  • GSK Investigational Site
    High Point, North Carolina 27262, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27615, United States
  • GSK Investigational Site
    Fargo, North Dakota 58103, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45219, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45236, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Cleveland, Ohio 44195, United States
  • GSK Investigational Site
    Dayton, Ohio 45406, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States

Showing the first 100 of 151 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bakris GL, Iyengar M, Lukas MA, Ordronneau P, Weber MA. Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study. J Clin Hypertens (Greenwich). 2010 Sep;12(9):678-86. doi: 10.1111/j.1751-7176.2010.00341.x. Epub 2010 Jul 8. PubMed 20883227 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2006
First posted
Jul 4, 2006
Start
Jul 2006
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Nov 9, 2009
Last update
Dec 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00347360
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 4, 2006
Start date
Jul 2006
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Nov 9, 2009
Last update
Dec 26, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisinopril

Start the discussion